Healthcare Industry News:  angiotensin II 

Biopharmaceuticals Cardiology Generics Distribution

 News Release - May 22, 2013

Par Pharmaceutical Begins Shipment of Generic Atacand(R)

WOODCLIFF LAKE, N.J., May 22, 2013 -- (Healthcare Sales & Marketing Network) -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca to distribute the authorized generic version of AstraZeneca's Atacand® (candesartan cilexetil). Par has begun shipping 4 mg, 8 mg, 16 mg and 32 mg strengths of candesartan cilexetil tablets. According to IMS Health data, annual U.S. sales of Atacand® are approximately $113 million.

Important Information About Candesartan Cilexetil Tablets

Candesartan cilexetil is an angiotensin II receptor blocker indicated for the treatment of hypertension in adults and children.

Candesartan cilexetil is contraindicated in patients who are hypersensitive to any component of the product. A black box warning is associated with this product regarding fetal toxicity. When pregnancy is detected, candesartan cilexetil should be discontinued as soon as possible. Drugs that act directly on the rennin-angiotensin system can cause injury and death to the developing fetus. Refer to full prescribing information for complete boxed warnings.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit

Source: Par Pharmaceutical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.